Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.

Nicholas EvageliouLindsay A RenfroJames I GellerElizabeth PerlmanJohn KalapurakalArnold C PaulinoDavid DixMeryle J EklundAndrew Jackson MurphyRodrigo L P RomaoPeter F EhrlichCarly R VarelaKelly VallanceConrad V FernandezJeffrey S DomeElizabeth A Mullen

Published in: Cancer (2023)

Findings confirm LN+ status as an adverse prognostic factor amplified by presence of singular LOH 1p or 16q, supporting study of intensified therapy for patients with LN+ in combination with singular LOH in a prospective clinical trial.

Keyphrases

prognostic factors
lymph node
clinical trial
young adults
palliative care
open label
emergency department
squamous cell carcinoma
radiation therapy
phase ii
study protocol
double blind
adverse drug
phase iii
placebo controlled